首页 | 本学科首页   官方微博 | 高级检索  
检索        

血浆凝血因子VIII水平与IgA肾病患者临床病理改变及预后的关系
引用本文:吴灵芝,谭夏,刘帝,陈国纯,刘煜,刘虹.血浆凝血因子VIII水平与IgA肾病患者临床病理改变及预后的关系[J].中华肾脏病杂志,2020,36(4):278-285.
作者姓名:吴灵芝  谭夏  刘帝  陈国纯  刘煜  刘虹
作者单位:中南大学湘雅二医院肾内科湖南省肾脏病与血液净化重点实验室
基金项目:国家自然科学基金(81770714、81470947、81570622)。
摘    要:目的探讨血浆凝血因子VIII(factor VIII,FVIII)水平与IgA肾病(IgAN)患者临床参数及预后的关系。方法收集2016年1月至2016年12月中南大学湘雅二医院确诊的IgAN患者的临床资料。按照时间依赖的受试者工作特征曲线(ROC)得出的血浆FVIII预测IgAN预后的临界值,将患者分为高FVIII组(FVIII>140.50%)和低FVIII组(FVIII≤140.50%),比较两组患者肾活检时基线临床参数的差异。以估算肾小球滤过率(eGFR)下降≥30%或进入终末期肾脏病(ESRD)为终点事件,采用Kaplan-Meier生存曲线及Cox回归方程法分析血浆FVIII水平对IgAN患者预后的影响。结果共93例IgAN患者纳入本研究,中位随访时间为35.15(33.77,36.76)个月,12例(12.90%)患者发生终点事件。高FVIII组患者年龄、血肌酐、尿素氮、血三酰甘油、血总胆固醇、血浆纤维蛋白原、D-二聚体、24 h尿蛋白量、蛋白C、蛋白S和eGFR下降速率高于低FVIII组(均P<0.05);eGFR、血白蛋白、中位随访时间低于低FVIII组(均P<0.05)。Kaplan-Meier生存分析结果显示,与低FVIII组比较,高FVIII组患者肾脏累积生存率降低(χ2=5.635,P=0.018)。在校正收缩压、eGFR、尿蛋白、肾小管萎缩/间质纤维化程度等因素后,多因素Cox回归分析结果显示,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素(HR=4.147,95%CI 1.055~16.308,P=0.042)。结论血浆FVIII水平与IgAN患者临床指标及预后相关,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素。

关 键 词:肾小球肾炎  IgA  因子VIII  预后  终末期肾脏病

Association between plasma factor VIII level and clinical indicators and prognosis in patients with IgA nephropathy
Wu Lingzhi,Tan Xia,Liu Di,Chen Guochun,Liu Yu,Liu Hong.Association between plasma factor VIII level and clinical indicators and prognosis in patients with IgA nephropathy[J].Chinese Journal of Nephrology,2020,36(4):278-285.
Authors:Wu Lingzhi  Tan Xia  Liu Di  Chen Guochun  Liu Yu  Liu Hong
Institution:Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha 410011, China; Corresponding author: Liu Hong, Email: liuhong618@csu.edu.cn
Abstract:Objective To investigate the relationship between plasma factor VIII (FVIII) level and the clinical indicators and prognosis in IgA nephropathy (IgAN) patients. Methods The clinical data of IgAN patients diagnosed from the Second Xiangya Hospital of Central South University from January 2016 to December 2016 were collected. Patients were divided into high FVIII group (FVIII>140.50%) and low FVIII group (FVIII≤140.50%) according to the time-dependent receiver operating characteristic curve analysis. The baseline clinical parameters at the time of renal biopsy between two groups of patients were compared. Taking the estimated glomerular filtration rate (eGFR) reduction ≥30% or entering end-stage renal disease (ESRD) as the endpoint event, Kaplan-Meier analysis and Cox proportional hazards models were used to explore the association between plasma FVIII level and prognosis in IgAN patients. Results A total of 93 patients were ultimately retained for this study, with a median follow-up of 35.15(33.77, 36.76) months. Twelve (12.90%) patients reached the endpoint event. The levels of serum creatinine, urea nitrogen, triglyceride, total cholesterol, plasma fibrinogen, D-dimer, 24-hour urinary protein, protein C, protein S, slope of eGFR and age in the high FVIII group were higher than those in the low FVIII group (all P<0.05). The levels of eGFR, serum albumin and follow-up time in the high FVIII group were lower than those in the low FVIII group (all P<0.05). The renal cumulative survival rate was significantly lower in the high FVIII group than that in the low FVIII group ( χ2=5.635, P=0.018) according to the Kaplan-Meier analysis. After adjusting for variables such as systolic blood pressure, eGFR, urinary protein, and renal tubular atrophy/interstitial fibrosis, multivariate Cox proportional hazards models analysis showed that high level of plasma FVIII was an independent risk factor for poor prognosis in IgAN patients (HR=4.147, 95%CI 1.055-16.308, P=0.042). Conclusions The level of plasma FVIII is associated with clinical indicators and prognosis in IgAN patients. The higher level of plasma FVIII can be identified as an independent risk factor for poor prognosis in IgAN patients.
Keywords:Glomerulonephritis  IgA     Factor VIII     Prognosis     End-stage renal disease  
本文献已被 维普 等数据库收录!
点击此处可从《中华肾脏病杂志》浏览原始摘要信息
点击此处可从《中华肾脏病杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号